551 related articles for article (PubMed ID: 23508577)
1. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
Murray-Stewart T; Woster PM; Casero RA
Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
[TBL] [Abstract][Full Text] [Related]
2. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
[TBL] [Abstract][Full Text] [Related]
3. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes.
Huang Y; Stewart TM; Wu Y; Baylin SB; Marton LJ; Perkins B; Jones RJ; Woster PM; Casero RA
Clin Cancer Res; 2009 Dec; 15(23):7217-28. PubMed ID: 19934284
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
5. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes.
Huang Y; Greene E; Murray Stewart T; Goodwin AC; Baylin SB; Woster PM; Casero RA
Proc Natl Acad Sci U S A; 2007 May; 104(19):8023-8. PubMed ID: 17463086
[TBL] [Abstract][Full Text] [Related]
8. Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells.
Zhu Q; Huang Y; Marton LJ; Woster PM; Davidson NE; Casero RA
Amino Acids; 2012 Feb; 42(2-3):887-98. PubMed ID: 21805138
[TBL] [Abstract][Full Text] [Related]
9. New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
Hoang N; Zhang X; Zhang C; Vo V; Leng F; Saxena L; Yin F; Lu F; Zheng G; Bhowmik P; Zhang H
Bioorg Med Chem; 2018 May; 26(8):1523-1537. PubMed ID: 29439916
[TBL] [Abstract][Full Text] [Related]
10. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
12. Polyamine analogues targeting epigenetic gene regulation.
Huang Y; Marton LJ; Woster PM; Casero RA
Essays Biochem; 2009 Nov; 46():95-110. PubMed ID: 20095972
[TBL] [Abstract][Full Text] [Related]
13. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1.
Lynch JT; Cockerill MJ; Hitchin JR; Wiseman DH; Somervaille TC
Anal Biochem; 2013 Nov; 442(1):104-6. PubMed ID: 23911524
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1.
Hazeldine S; Pachaiyappan B; Steinbergs N; Nowotarski S; Hanson AS; Casero RA; Woster PM
J Med Chem; 2012 Sep; 55(17):7378-91. PubMed ID: 22876979
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures.
Nowotarski SL; Pachaiyappan B; Holshouser SL; Kutz CJ; Li Y; Huang Y; Sharma SK; Casero RA; Woster PM
Bioorg Med Chem; 2015 Apr; 23(7):1601-12. PubMed ID: 25725609
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4.
Metzger E; Imhof A; Patel D; Kahl P; Hoffmeyer K; Friedrichs N; Müller JM; Greschik H; Kirfel J; Ji S; Kunowska N; Beisenherz-Huss C; Günther T; Buettner R; Schüle R
Nature; 2010 Apr; 464(7289):792-6. PubMed ID: 20228790
[TBL] [Abstract][Full Text] [Related]
17. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R
Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389
[TBL] [Abstract][Full Text] [Related]
18. (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators.
Sharma SK; Wu Y; Steinbergs N; Crowley ML; Hanson AS; Casero RA; Woster PM
J Med Chem; 2010 Jul; 53(14):5197-212. PubMed ID: 20568780
[TBL] [Abstract][Full Text] [Related]
19. Silencing of LSD1 gene modulates histone methylation and acetylation and induces the apoptosis of JeKo-1 and MOLT-4 cells.
Zou ZK; Huang YQ; Zou Y; Zheng XK; Ma XD
Int J Mol Med; 2017 Aug; 40(2):319-328. PubMed ID: 28627608
[TBL] [Abstract][Full Text] [Related]
20. Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD1 in cancer cells.
Han H; Yang X; Pandiyan K; Liang G
PLoS One; 2013; 8(9):e75136. PubMed ID: 24040395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
